5'- AM-C6 ca**G$_S$A$_S$G$_S$**a$_S$a$_S$g$_S$g$_S$c$_S$a$_S$c$_S$a$_S$g$_S$a$_S$ ^{m}**C$_S$G$_S$G**-3' (SEQ ID NO: 305)

5'- AM-C6 ca**G$_S$** ^{m}**C$_S$G$_S$**a$_S$a$_S$g$_S$t$_S$g$_S$c$_S$a$_S$c$_S$a$_S$ ^{m}**C$_S$G$_S$G**-3' (SEQ ID NO: 307)

5'- AM-C6 ca**A$_S$G$_S$G$_S$**t$_S$g$_S$a$_S$a$_S$g$_S$ ^{m}c$_S$g$_S$a$_S$a$_S$g$_S$**T$_S$G$_S$** ^{m}**C**-3' (SEQ ID NO:315)

5'- AM-C6 ca**A$_S$G$_S$G$_S$**t$_S$g$_S$a$_S$a$_S$g$_S$ ^{m}c$_S$g$_S$a$_S$a$_S$**G$_S$T$_S$G**-3' (SEQ ID NO: 316)

5'- AM-C6 ca ^{m}**C$_S$G$_S$A$_S$**a$_S$c$_S$c$_S$a$_S$c$_S$t$_S$g$_S$a$_S$**A$_S$** ^{m}**C$_S$A**-3' (SEQ ID NO: 297)

5'- AM-C6 ca ^{m}**C$_S$G$_S$A$_S$**a$_S$c$_S$c$_S$a$_S$c$_S$t$_S$g$_S$a$_S$**A$_S$** ^{m}**C**-3' (SEQ ID NO: 298)

5'- AM-C6 ca ^{m}**C$_S$G$_S$** ^{m}**C$_S$**a$_S$g$_S$t$_S$a$_S$t$_S$g$_S$g$_S$a$_S$**T$_S$** ^{m}**C**-3' (SEQ ID NO: 300)

5'- AM-C6 ca**G$_S$A$_S$A$_S$**g$_S$t$_S$g$_S$c$_S$a$_S$c$_S$a$_S$ ^{m}c$_S$**G$_S$G**-3' (SEQ ID NO: 306)

5'-AM-C6 ca ^{m}**C$_S$G$_S$A$_S$**a$_S$g$_S$t$_S$g$_S$c$_S$a$_S$c$_S$a$_S$ ^{m}**C$_S$G**-3' (SEQ ID NO: 309)

5'-AM-C6 ca**A$_S$G$_S$G$_S$**t$_S$g$_S$a$_S$a$_S$g$_S$ ^{m}c$_S$g$_S$a$_S$**A$_S$G$_S$T**-3' (SEQ ID NO: 317)

5'-AM-C6 ca**G$_S$A$_S$A$_S$**c$_S$c$_S$a$_S$c$_S$t$_S$g$_S$a$_S$a$_S$ ^{m}**C$_S$A$_S$A$_S$A**-3' (SEQ ID NO: 585)

5'-AM-C6 ca ^{m}**C$_S$G$_S$A$_S$A$_S$**c$_S$c$_S$a$_S$c$_S$t$_S$g$_S$a$_S$a$_S$c$_S$**A$_S$A$_S$A**-3' (SEQ ID NO: 588)

5'-AM-C6 ca**G$_S$A$_S$A$_S$**g$_S$t$_S$g$_S$c$_S$a$_S$c$_S$a$_S$ ^{m}**C$_S$G$_S$G**-3' (SEQ ID NO: 628)

5'-AM-C6 ca**T$_S$A$_S$G$_S$**t$_S$a$_S$a$_S$a$_S$c$_S$t$_S$g$_S$a$_S$g$_S$ ^{m}**C$_S$** ^{m}**C$_S$A$_S$**3' (SEQ ID NO: 678)

5'-AM-C6 ca ^{m}**C$_S$G$_S$A$_S$**a$_S$c$_S$c$_S$a$_S$c$_S$t$_S$g$_S$**A$_S$A$_S$** ^{m}**C**-3' (SEQ ID NO: 600), and

5'-AM-C6 ca ^{m}**C$_S$G$_S$A$_S$**a$_S$c$_S$c$_S$a$_S$c$_S$t$_S$g$_S$**A$_S$A$_S$** ^{m}**C$_S$A**-3' (SEQ ID NO: 597),

wherein, uppercase letters denote beta-D-oxy-LNA units; lowercase letters denote DNA units; the subscript "s" denotes a phosphorothioate linkage; superscript m denotes a DNA or beta-D-oxy-LNA unit containing a 5-methylcytosine base; AM-C6 is an amino-C6 linker; wherein the 5' terminal group "AM-C6 c a" is optional.

18. A pharmaceutical composition comprising an oligomer conjugate according to any one of claims 1 to 14; or an oligomer according to any one of claims 15 to 17 and one or more pharmaceutically acceptable diluents, carriers, salts or adjuvants.

~~19. An oligomer conjugate for use in the treatment of a viral disorder, wherein said oligomer conjugate comprises:~~

~~a) at least one first oligomer region capable of modulating a target sequence of Hepatitis B Virus (HBV), preferably HBx or HBsAg of HBV, to treat said viral disorder; and~~

~~b) a carrier component for delivering said first oligomer to the liver.~~

~~20. An oligomer conjugate for the use according to claim 1~~19~~, wherein said oligomer conjugate is an oligomer conjugate as defined in any one of claims 1 to 12.~~

~~21. The oligomer conjugate for use according to claim 19 or 20, wherein said oligomer conjugate is administered subcutaneously.~~

19. The oligomer conjugate for use in the treatment of a viral disorder in the liver, wherein said oligomer conjugate is an oligomer conjugate as defined in any one of claims 1 to 14, and wherein said oligomer conjugate is to be administered subcutaneously.

20. Use of the oligomer conjugate as defined in any one of claims 1 to 14 in the manufacture of a medicament for the treatment of a viral disorder in the liver, wherein said oligomer conjugate is to be administered subcutaneously.